Biotech

All Articles

Transgene's viral cancer vaccination fails midphase exam

.Transgene's healing vaccine candidate TG4001 has failed a period 2 sound lump trial. But, while the...

Upstream swells IPO to $255M as it provides together with CAMP4

.Upstream Bio has inflamed its IPO to $255 million as the provider signs up with CAMP4 Therapeutics ...

Sanofi flunks MS study, giving another strike to Denali pact

.Sanofi has actually stopped a period 2 ordeal of Denali Therapeutics-partnered oditrasertib in seve...

Turnstone lays off 60%, agitates C-suite to stretch out money

.Turnstone Biologics is actually decreasing its own headcount through 60% as well as shaking up its ...

Gilead loses hope on $15M MASH bet after mulling preclinical records

.In a year that has viewed an approval and also a boating of readouts for metabolic dysfunction-asso...

Texas biotech centers cancer cells contract, pins hopes on excessive weight

.Alaunos Therapies is actually axing an agreement with Precigen, losing hope licensing civil rights ...

Capricor portions much more information for DMD therapy after triggering BLA

.Capricor Therapies is actually taking a triumph lap for their stage 2 Duchenne muscular dystrophy (...

FDA areas Kezar lupus trial in grip following 4 person deaths

.The FDA has placed Kezar Life Sciences' lupus test on grip after the biotech flagged four deaths th...

Phase 3 Historian Rock test hits SMA target, delivering stock up 200%

.A period 3 test of Historian Rock's vertebral muscle atrophy (SMA) applicant has hit its main endpo...

CAMP 4 is most current to eye IPO, while Upstream define $182M planning

.RNA biotech CAMP4 Rehabs has actually marked out prepare for a $67 million IPO, with inflammation-f...